• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell biochemistry and function >Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF- and TGF-
【24h】

Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF- and TGF-

机译：骨髓间充质干细胞对博来霉素诱导的肺纤维化的抑制作用可能是通过降低MMP9，TIMP-1，INF-和TGF-

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The study was aimed to investigate the mechanism and administration timing of bone marrow-derived mesenchymal stem cells (BMSCs) in bleomycin (BLM)-induced pulmonary fibrosis mice. Thirty-six mice were divided into six groups: control group (saline), model group (intratracheal administration of BLM), day 1, day 3 and day 6 BMSCs treatment groups and hormone group (hydrocortisone after BLM treatment). BMSCs treatment groups received BMSCs at day 1, 3 or 6 following BLM treatment, respectively. Haematoxylin and eosin and Masson staining were conducted to measure lung injury and fibrosis, respectively. Matrix metalloproteinase (MMP9), tissue inhibitor of metalloproteinase-1 (TIMP-1), -interferon (INF-) and transforming growth factor 1 (TGF-) were detected in both lung tissue and serum. Histologically, the model group had pronounced lung injury, increased inflammatory cells and collagenous fibres and up-regulated MMP9, TIMP-1, INF- and TGF- compared with control group. The histological appearance of lung inflammation and fibrosis and elevation of these parameters were inhibited in BMSCs treatment groups, among which, day 3 and day 6 treatment groups had less inflammatory cells and collagenous fibres than day 1 treatment group. BMSCs might suppress lung fibrosis and inflammation through down-regulating MMP9, TIMP-1, INF- and TGF-. Delayed BMSCs treatment might exhibit a better therapeutic effect. Copyright (c) 2015 John Wiley & Sons, Ltd.
机译：该研究旨在探讨博来霉素（BLM）诱导的肺纤维化小鼠骨髓源性间充质干细胞（BMSCs）的机制和给药时机。将36只小鼠分为六组：对照组（盐水），模型组（BLM经气管内给药），BMSCs治疗的第1、3、6天和荷尔蒙组（BLM治疗后氢化可的松）。 BMSC治疗组分别在BLM治疗后的第1、3或6天接受BMSC。苏木精和曙红和Masson染色分别用于测量肺损伤和纤维化。在肺组织和血清中均检测到基质金属蛋白酶（MMP9），金属蛋白酶-1（TIMP-1）的组织抑制剂，干扰素（INF-）和转化生长因子1（TGF-）。从组织学上看，模型组与对照组相比，肺损伤明显，炎症细胞和胶原纤维增多，MMP9，TIMP-1，INF-和TGF-上调。在BMSCs治疗组中，肺部炎症和纤维化的组织学表现以及这些参数的升高均受到抑制，其中，第3天和第6天治疗组的炎症细胞和胶原纤维少于第1天治疗组。 BMSC可能通过下调MMP9，TIMP-1，INF-和TGF-来抑制肺纤维化和炎症。延迟的骨髓间充质干细胞治疗可能显示出更好的治疗效果。版权所有（c）2015 John Wiley＆Sons，Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号